---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-012053"
form_type: "8-K"
ticker: "GLSI"
cik: "0001799788"
company_name: "Greenwich LifeSciences, Inc."
filed_at: "2023-04-13T23:59:59+00:00"
generated_at: "2026-06-17T02:44:34.204651+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Greenwich LifeSciences confirms FDA review of Phase IIb data, provides Flamingo-01 trial update

## Summary
- FDA reviewed Phase IIb clinical data before Flamingo-01 Phase III trial commencement.
- First US sites activated in Q3 2022; patient enrollment and treatment ongoing since Q4 2022.
- DTH skin tests and blood samples collected to assess immune response.
- Company planning expansion of Flamingo-01 clinical trial into Europe.
- Abstract and poster on Flamingo-01 design presented at AACR on April 17, 2023.

## SEC filing metadata
- accession: 0001493152-23-012053
- form_type: 8-K
- ticker: GLSI
- cik: 0001799788
- company_name: Greenwich LifeSciences, Inc.
- filed_at: 2023-04-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799788/000149315223012053/0001493152-23-012053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799788/000149315223012053/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-012053
- JSON: https://secwatch.observer/filing/0001493152-23-012053.json
- Plain text: https://secwatch.observer/filing/0001493152-23-012053.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.